AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of multiple doses of
AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC